Erez Chimovits - 05 Aug 2026 Form 3 Insider Report for Braveheart Bio, Inc. (BRVE)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BRVE
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 05 Aug 2026, 21:07:39 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ James Paul Rickey, Attorney-in-Fact

Key filing fact

Erez Chimovits filed Form 3 for Braveheart Bio, Inc. (BRVE) on 05 Aug 2026.

Key facts

This page summarizes Erez Chimovits's Form 3 filing for Braveheart Bio, Inc. (BRVE).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2026, 21:07.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001706399 Primary reporting owner

Chimovits Erez

Relationship: Director, 10%+ Owner
Address: C/O BRAVEHEART BIO, INC., ONE LETTERMAN DR., BLDG. A, SUITE A4-300, SAN FRANCISCO
Signature: /s/ James Paul Rickey, Attorney-in-Fact
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BRVE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,102,739
Date: 05 Aug 2026
Ownership: By OrbiMed Private Investments IX, LP
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BRVE holding Derivative

Series A Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: By OrbiMed Private Investments IX, LP
Underlying class: Common Stock
Underlying amount: 9,132,420
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Footnote F2

Each of the Reporting Person, OrbiMed Advisors, and GP IX disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP IX is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-4.38 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

SEC remarks

Exhibit 24 - Power of Attorney